A Phase 4 interventional study of remifentanil and laryngeal mask airway (LMA) in Drug Usage, sponsored by Ajou University School of Medicine. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Ajou University School of Medicine · Phase 4, Interventional, and Treatment
The investigators attempted to determine the optimal effect-site concentration of remifentanil for smooth removal of the LMA from propofol anesthesia.
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). LMA removal was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
Ajou University School of Medicine is the lead sponsor of 171 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
Drug: remifentanil · Device: laryngeal mask airway (LMA)
The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
Also known as: Ultiva
LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
smooth removal of LMA
the response of patients to the removal of LMA (classified as either 'success \[smooth emergence\]' or 'failure') during infusion of remifentanil.
Time frame: from end of surgery to removal of LMA (participants will be followed for the emergence periods, an expected average of 15 min).
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ajou University School of Medicine